Survival benefit of concurrent chemoradiotherapy for advanced ampulla of Vater cancer

Table 2 Univariate and multivariate analyses for overall survival

	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Sex (male)	1.752 (0.5667-5.416)	0.33
Age	0.992 (0.9545-1.031)	0.693
Size	0.924 (0.6395-1.334)	0.672
T stage	2.102 (0.6376-6.927)	0.222	3.015 (0.989-9.159)	0.052
LN metastasis (positive)	2.596 (0.967-6.968)	0.058	3.702 (1.116-12.283)	0.032a
LVI (positive)	3.35 (1.226-9.153)	0.018a	1.806 (0.549-5.941)	0.33
PNI (positive)	1.344 (0.5331-3.39)	0.531
Differentiation (poor)	1.398 (0.5406-3.617)	0.489
CCRT	1.073 (0.423-2.724)	0.881
Bilirubin	0.966 (0.8975-1.04)	0.359
CEA (≥ 5 ng/mL)	0.423 (0.0555-3.226)	0.407
CA19.9 (≥ 39 U/L)	1.372 (0.475-3.963)	0.559
CRP (≥ 0.5 mg/mL)	3.503 (0.7991-15.35)	0.096
Albumin (< 3.3 or > 5.2 mg/dL)	3.088 (0.6807-14.01)	0.144
PLR	1.003 (0.9991-1.007)	0.128
NLR	1.061 (0.9529-1.18)	0.282

^aP < 0.05.

LN: Lymph node; LVI: Lymphovascular invasion; PNI: Perineural invasion; CCRT: Concurrent chemoradiotherapy; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CRP: C-reactive protein; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; HR: Hazard ratio; CI: Confidence interval.